EPHA2 and cancer: When these CAR-T cells were coupled with another group of CAR-T cells that targeted the EphA2 antigen on the A549 cancer cells, significantly improved antitumor activity and survival rates in the mice were observed compared to the treatment with EphA2-specific CAR-T cells alone [102].